| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014118556 |
| Title |
Selective Inhibitors and Allosteric Activators of Sphingosine Kinase. |
| Abstract |
Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases, such as cancer and vascular remodeling in pulmonary arterial hypertension. Inhibitors of sphingosine kinase 1 and 2 (SK1 and SK2), which catalyze the synthesis of S1P, may be useful anti- proliferative agents. We have synthesized a series of sphingosine-based inhibitors of SK and SK2. Also provided in this invention are compounds that activate SK1 which can be used in diseases such as fibrosis, where intracellular S1P is anti-fibrotic. |
| Applicant(s) |
Research Foundation of the City University of New York |
| Representative Drug(s) |
D0DG7E |
Drug Info
|
IC50 = 2 nM |
Click to Show More |
[1] |
|
2
|
D0VB2X
|
Drug Info
|
IC50 = 3.6 nM
|
[1] |
| Patent ID |
WO2014157382 |
| Title |
Sphingosine Kinase Inhibitor. |
| Abstract |
The present invention relates to a sphingosine kinase inhibitor comprising a compound represented by formula (I) [wherein each symbol is as defined in the description] or a salt thereof, and provides. |
| Applicant(s) |
Ajinomoto Co., Inc |
| Representative Drug(s) |
D07QBL |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0H1BQ
|
Drug Info
|
N.A.
|
[1] |
|
3
|
D0HM6Q
|
Drug Info
|
N.A.
|
[1] |
|
4
|
D0QT5B
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2012069852 |
| Title |
Pharmaceutical Compounds As Inhibitors of Sphingosine Kinase. |
| Abstract |
The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of sphingosine kinase. Particularly, although not exclusively, the present invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment and/or prevention of cancers, hyperproliferative, inflammatory, angiogenic, immune and viral infectious diseases. |
| Applicant(s) |
Almac Discovery Limited |
| Representative Drug(s) |
D02DLL |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0RE9W
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2010033701 |
| Title |
Inhibitors of Sphingosine Kinase 1. |
| Abstract |
The invention relates to compounds of Formula (I). Compounds of the present invention are inhibitors of sphingosine kinase 3, and are useful in the treatment of various disorders and conditions, such as inflammatory disorders. |
| Applicant(s) |
Genzyme Corporation |
| Representative Drug(s) |
D0G2TX |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0TR9T
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2016007993 |
| Title |
Benzene Sulfonamide-Based Inhibitors of Sphingosine Kinase. |
| Abstract |
A novel class of sphingosine kinase (SK) inhibitor compounds are disclosed which are useful in the treatment of cancer and other proliferative cell conditions. The compounds are benzene sulfonamides with a chemical structure according to formula (I). |
| Applicant(s) |
Central Adelaide Local Health Network Inc |
| Representative Drug(s) |
D04VDD |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013119946 |
| Title |
Long Chain Base Sphingosine Kinase Inhibitors. |
| Abstract |
The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors. |
| Applicant(s) |
University of Virginia Patent Foundation |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US8372888 |
| Title |
Novel Sphk1 Inhibitors,Compositions and Processes. |
| Applicant(s) |
Enzo Therapeutics |
| Patent ID |
US8314151 |
| Title |
Sphk1 Inhibitors and Processes Using The Same. |
| Applicant(s) |
Enzo Therapeutics |
